Event > Conference >
WORD+ 2025
WORD+ 2025 is THE in person event for Organoid and Organ-on-a-chip researchers where we are silver sponsors! This exciting event brings together leading experts in the field of organoid and organ-on-a-chip research to share their latest findings and advancements.
It was great to meet you at WORD!
Spotlight Session
Taking Organoids to the Next Level: How microphysiological systems close the gap between in vitro assays and the human
Date: Monday 11 February 2025
Time: 12:30
Presentation from: Sung Lee, CN Bio
Training Day
How to maximise your success with Organ-on-a-chip in your lab: Essential Strategies and Expert Suggestions
Date: Thursday 13 February
Time: 10:30am
Presentation from: Dr. Atefeh Mobasseri, CN Bio
Poster
A human liver microphysiological system for assessing drug-induced liver injury and mechanisms of toxicity
Find us at poster 68!
Our Team at WORD+ 2025
Atefeh
Dr Atefeh Mobasseri, Field Application Scientist at CN Bio, has an extensive background in tissue engineering and regenerative medicine. Before joining CN Bio, she gained a PhD in Biomedical materials from the University of Manchester and carried out postdoctoral roles at the University of Manchester and Kings College London investigating the interaction, and effect, of 3D scaffolds on cellular behaviour. Since joining CN Bio, she has been supporting their European customers in using CN Bio’s range of PhysioMimix® systems to generate high content, human-relevant, data.
Sung
A seasoned life science professional with over 20 years of experience in product management, product marketing, and commercial leadership, Sung Lee joined CN Bio as a Director of Product Management in October 2024. He brings valuable experience in the assay kit market from his most recent role at Abcam, where he was the global lead as the senior product director for the Assay Kits and Protein product portfolio. He has held various leadership roles at renowned companies like Abcam (Danaher Company), Epitomics (‘The Rabbit Monoclonal Company’), and Life Technologies (Thermo Fisher Scientific). Sung’s education background includes business certifications from Cambridge Judge Business School and Wharton Business School, and a degree in Molecular and Developmental Biology from the University of California, Santa Cruz.
Adrian
A seasoned business developer with extensive commercial experience in the life science sector, Adrian Rea joined CN Bio as the European Director of Sales in June 2022. He brings valuable experience in the 3D cell culture market from his most recent role at InSphero, where he was responsible for developing business opportunities in European and Asian markets. He was previously Sales Director at Enzo Life Sciences, where he managed the restructuring of the global distributor sales channels and expanding the European sales operations. Adrian graduated from the University of Glasgow and received his PhD in pharmacology from Glasgow Caledonian University.
Audrey
Dr Audrey Dubourg is CN Bio’s Product Manager for the PhysioMimix® OOC range of microphysiological systems. Prior to joining CN Bio, she worked as a postdoctoral scholar at the University of California – Los Angeles (UCLA), in the US, in the Microbiology, Immunology and Molecular Genetics department. She completed an MSc in microbiology at the University of Montpellier II, followed by a PhD in microbiology/parasitology at the University of East Anglia. Audrey has extensive experience in the disciplines of molecular biology and 3D mammalian cell culture. Since joining CN Bio, she has been actively involved in promoting the benefits of incorporating organ-on-a-chip technology into drug discovery and development workflows.
Dave
David Sampson joined CN Bio in September 2024 as Sales Manager for Northern Europe. He brings around 20 years commercial experience within the life sciences industry. In his previous roles at global organisations, including Tecan and Beckman Coulter Life Sciences, he was responsible for supplying automated solutions and assay miniaturisation technology to pharmaceutical, biotech and academic organisations, whilst addressing a broad range of applications. David graduated from the University of Birmingham and received his PhD in endocrinology from University College London.